David Russler-Germain: Swapping in BrECADD for PET adapted approaches

David Russler-Germain, Oncology Instructor at Siteman Cancer Center, shared a post by Graham Collins, Associate Professor of Haematology and lymphoma specialist at Oxford Cancer and Haematology Centre, shared on X:

“I’m curious whether we (USA) would/should start swapping in BrECADD for PET adapted approaches where we would escalate to escBEACOPP? Maybe?”

Quoting Graham Collins’s post:

“Borchmann – HD21

• 1500 pts, escBEACOPP v BrCADD 1L cHL
• Less Rx-related morbidity (mainly Hb/plt Tx)
• Higher delivery of chemo intensity
• better PFS: 93% at 4year !
• OS no diff
• IPS 3+ did a little worse than 0-2

Incredible results! Practise changing study.”

Source: David Russler-Germain/X and Graham Collins/X